Opto Circuit is currently trading at Rs. 134.65, up by 5.05 points or 3.90% from its previous closing of Rs. 129.60 on the BSE.
The scrip opened at Rs. 129.40 and has touched a high and low of Rs. 135.90 and Rs. 128.55 respectively. So far 366751 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 225.32 on 17-Feb-2012 and a 52 week low of Rs. 114.70 on 29-Aug-2012.
Last one week high and low of the scrip stood at Rs. 135.90 and Rs. 123.55 respectively. The current market cap of the company is Rs. 3265.25 crore.
The promoters holding in the company stood at 28.15% while Institutions and Non-Institutions held 37.29% and 34.56% respectively.
Opto Circuit’s subsidiary, Opto Eurocor Healthcare, has launched its first Sirolimus Drug Eluting Stent (DES), E-MAGIC plus on receipt of Drug Controller General of India (DCGI) license to sell and market products in India. With the launch of E-MAGIC Plus, Opto Circuits becomes one of the few global players to offer DES products with choice of two drugs coatings.
E-MAGIC plus consists of a balloon expandable intra coronary chromium stent pre-mounted on a custom balloon delivery system with a Sirolimus coating (also known as Rapamycin), into the arterial wall. Sirolimus helps control excess growth of cells and allows the artery to heal. Further, E-magic plus stent has an extra edge with soft tip technology to provide smooth access to the lension site ensuring minimal trauma to the vessel wall.
The Sirolimus DES market is estimated to be worth of Rs 800 crore in India. E-Magic has been developed indigenously in India and with DCGI mark; the company can market and sell in India. Meanwhile, the DGCI approval will also enable E-Magic Plus to be marketed in parts of Far East and parts of Middle East.
| Company Name | CMP |
|---|---|
| Lenskart Solutions | 534.85 |
| Poly Medicure | 1468.25 |
| Laxmi Denta | 195.10 |
| Nureca Ltd. | 263.80 |
| Hemant Surgical Inds | 297.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: